RT Journal Article
SR Electronic
T1 439 Primary symptoms in women with different histopathological subtypes of gynaecological sarcoma – results of a prospective intergroup registry for gynaecological sarcoma (REGSA – NOGGO RU1)
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A182
OP A182
DO 10.1136/ijgc-2020-IGCS.380
VO 30
IS Suppl 3
A1 E Roser
A1 K Pietzner
A1 S Brucker
A1 P Harter
A1 D Zocholl
A1 A Gimpel
A1 M Kalder
A1 M Bossart
A1 H Strauß
A1 P Wimberger
A1 R Armbrust
A1 C Marth
A1 T Fehm
A1 P Jurcikova
A1 A Mustea
A1 J Sehouli
YR 2020
UL http://ijgc.bmj.com/content/30/Suppl_3/A182.1.abstract
AB Introduction Gynaecological sarcomas are rare and there is very limited evidence about symptoms at primary diagnosis. Most knowledge is based on retrospective analysis.Methods We present data of 410 patients (pts) in the primary situation. Overall, 87.91% of pts had documented symptom data, which were analysed descriptively. A distinction was made between pre- (prem., ≤52 yrs) and postmenopausal (postm., >52 yrs.).Results The average age of pts was 56 yrs (range 15–88 yrs). Leiomyosarcoma (LMS) was diagnosed in 44.7%, endometrial stromal sarcoma (ESS) in 26.6% (62.6% low grade (LG-ESS) and 37.4% high grade (HG-ESS)). Undifferentiated sarcoma (US) and adenosarcoma (AS) were observed in 5.7% and 8.7% respectively. In prem. and postm. pts with LMS, the leading symptom (LS) was abdominal pain (ap) in 34.4%. and 39.5% respectively. In prem. HG-ESS the LS were ap and bleeding disorders (bd) in both 33.3%. In postm. HG-ESS and prem. LG-ESS the LS was vaginal bleeding (vb) in 29% and 33.3% respectively. In prem. AS the LS was ap in 27.3%, whereas in postm. AS it was postmenopausal bleeding (pb) in 29.2%. In prem. US the LS were bd and vb both at 66.7%. In postm. US the LS was ap in 47.4%.Conclusions We analyzed the LS of different histopathological subtypes in primary gynaecological sarcoma for the first time. Bleeding disorders and abdominal pain are the main symptoms in all subtypes. Symptoms are heterogeneous and about every 5th woman reported unspecific symptoms. This underlines the importance of awareness for gynaecological sarcoma.